Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing DAOIB for Long COVID

We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks.

Official registry: https://clinicaltrials.gov/study/NCT05764538 · Chang Gung Memorial Hospital · enrollment listed as 40

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are DAOIB. The registry lists allocation as na. We will enroll long-COVID patients with cognitive impairments.

They plan to enroll about 40 people at Kaohsiung City. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial

Interventions: DAOIB

Primary outcome (registry wording): Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24

Who it is for (from inclusion criteria)

  • Ages 18 Years to 100 Years
  • "post-COVID-19 condition" defined by WHO (symptoms present at three months after SARS-CoV-2 infection and last for at least 2 months which cannot be explained by an alternative diagnosis)(Cabrera Martimbianco, Pacheco et al. 2021) and COVID-induced cognitive impairments
  • physically healthy and have all laboratory assessments (including urine/blood routine, biochemical tests, and electrocardiograph) within normal limits
  • have sufficient education to communicate effectively and are capable of completing the assessments of the study

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phasePaiporta, Valencia
Not a traditional drug phase: Transcranial Direct Current Therapy (tDCS) for COVID-19

This study aims to verify the how well it works/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and myalgia, as well as sleep problems. Transcranial direct current stimulation is used in the field of Physiotherapy and Rehabilitation, with results that have proven to be effective for treating patients suffering from symptoms like migraines, headaches, chronic pain, fibromyalgia, or chronic neuropathic pain and insomnia.

NCT05780450 · Official ClinicalTrials.gov record · Fundación Universidad Católica de Valencia San Vicente Mártir

RecruitingNot a traditional drug phaseSaint-Denis
Not a traditional drug phase: Cardiac coherence for Long COVID

Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition ". Long COVID can affects any type of patient and has polymorphic and fluctuating symptoms over time.

NCT05851859 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de la Réunion

FAQ about this NCT record

Is NCT05764538 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT05764538?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT05764538?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary